EHA 2019 poster: PTC299 is a novel dihydroorotate dehydrogenase (DHODH) inhibitor for use in treatment of acute myeloid leukemia (AML)​

This poster provides the results of ex vivo experiments using a novel inhibitor of DHODH, to investigate its potential as a treatment for AML. It was presented at the 2019 EHA meeting in Amsterdam 

  • Results presented include the range of leukemia cell lines found to be sensitive to treatment with the DHODH inhibitor
  • Results showing activity against cancer cells in patient-derived xenografts mouse models are displayed, along with efficacy of the novel agent in primary AML blood samples from human patients
  • The mechanism of action by which the agent selectively targets AML cells by pyrimidine deprivation is presented
Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

  • PTC will delete immediately the information provided if we cannot confirm you are healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any enquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at:

You can unsubscribe from updates at any time when receiving an email from PTC.

MED-ALL-AML-2100046 | October 2021
Sign in or register to access exclusive content on this site 

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
MED-ALL-CORP-2200029 | December 2022


The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.